Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?

Key Points

• Theravance Biopharma shares crossed above their 50-day moving average, reaching $17.10 and closing near $17.06, compared with a 50-day average of $16.95.
• Analyst sentiment is largely cautious: the stock has a consensus “Hold” rating from MarketBeat, with an average price target of $19.40 after several recent downgrades.
• The company missed quarterly expectations, reporting an adjusted loss of $0.11 per share and revenue of $20.73 million versus estimates of $0.07 per share and $22.49 million; insiders have also sold roughly 350,000 shares over the past three months.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report)'s share price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $16.95 and traded as high as $17.10. Theravance Biopharma shares last traded at $17.06, with a volume of 251,659 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on TBPH shares. Wall Street Zen lowered Theravance Biopharma from a "buy" rating to a "hold" rating in a research note on Saturday, May 16th. JonesTrading downgraded Theravance Biopharma from a "buy" rating to a "hold" rating in a research report on Monday, June 29th. HC Wainwright cut shares of Theravance Biopharma from a "buy" rating to a "neutral" rating and boosted their price target for the stock from $15.00 to $17.00 in a research report on Tuesday, July 7th. BTIG Research lowered shares of Theravance Biopharma from a "buy" rating to a "neutral" rating in a research report on Monday, June 29th. Finally, Weiss Ratings raised shares of Theravance Biopharma from a "hold (c)" rating to a "hold (c+)" rating in a research note on Monday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat.com, Theravance Biopharma presently has a consensus rating of "Hold" and an average target price of $19.40.

Theravance Biopharma Stock Performance

The stock has a market cap of $885.76 million, a PE ratio of 16.89 and a beta of 0.25. The stock has a fifty day moving average price of $16.95 and a 200 day moving average price of $16.49.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.18). The company had revenue of $20.73 million for the quarter, compared to analysts' expectations of $22.49 million. Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. As a group, equities analysts anticipate that Theravance Biopharma, Inc. will post 1.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $16.39, for a total transaction of $218,216.46. Following the completion of the transaction, the senior vice president directly owned 232,457 shares of the company's stock, valued at approximately $3,809,970.23. The trade was a 5.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 37,799 shares of the company's stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $17.00, for a total transaction of $642,583.00. Following the transaction, the insider owned 9,174,453 shares in the company, valued at $155,965,701. The trade was a 0.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 350,011 shares of company stock worth $6,008,309. Insiders own 7.65% of the company's stock.

Institutional Trading of Theravance Biopharma

Several institutional investors have recently added to or reduced their stakes in TBPH. Quarry LP purchased a new position in shares of Theravance Biopharma during the third quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company's stock worth $40,000 after buying an additional 1,411 shares during the period. CIBC Private Wealth Group LLC lifted its stake in shares of Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company's stock worth $68,000 after acquiring an additional 4,662 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock worth $55,000 after acquiring an additional 781 shares during the last quarter. Finally, Virtus Advisers LLC purchased a new position in Theravance Biopharma during the 4th quarter valued at $170,000. Institutional investors own 99.10% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.